The DOI matches its Crossref record; 231 of the 232 references it cites were found in a registry or an index.
Cerebral amyloid angiopathy and Alzheimer disease — one peptide, two pathways
Open accessAbstract
The shared role of amyloid-β (Aβ) deposition in cerebral amyloid angiopathy (CAA) and Alzheimer disease (AD) is arguably the clearest instance of crosstalk between neurodegenerative and cerebrovascular processes. The pathogenic pathways of CAA and AD intersect at the levels of Aβ generation, its circulation within the interstitial fluid and perivascular drainage pathways and its brain clearance, but diverge in their mechanisms of brain injury and disease presentation. Here, we review the evidence for and the pathogenic implications of interactions between CAA and AD. Both pathologies seem to be driven by impaired Aβ clearance, creating conditions for a self-reinforcing cycle of increased vascular Aβ, reduced perivascular clearance and further CAA and AD progression. Despite the close relationship between vascular and plaque Aβ deposition, several factors favour one or the other, such as the carboxy-terminal site of the peptide and specific co-deposited proteins. Amyloid-related imaging abnormalities that have been seen in trials of anti-Aβ immunotherapy are another probable intersection between CAA and AD, representing overload of perivascular clearance pathways and the effects of removing Aβ from CAA-positive vessels. The intersections between CAA and AD point to a crucial role for improving vascular function in the treatment of both diseases and indicate the next steps necessary for identifying therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, brains from COVID patients also show ischemic and hemorrhagic lesions, as well as microglial activation [79], which can be seen in many AD patients with cerebral amyloid angiopathy [80].”
From What would it take to prove that a chronic infection is a causal agent in Alzheimer’s disease? (2025) · cites this paper as [80]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recently, vascular deposits of Aβ peptides (amyloid angiopathy) are increasingly recognized as a common pathology in AD cases, supporting that Aβ peptides circulate within the interstitial fluid, including CSF, and blood vessels through perivascular (e.g. lymphatic) drainage pathways during the crosstalk between the brain and the vascular system [77].”
From Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer’s disease (2020) · cites this paper as [77]
The cited source says what the claim attributes to it.
In the citing paper
“Recently, vascular deposits of Aβ peptides (amyloid angiopathy) are increasingly recognized as a common pathology in AD cases, supporting that Aβ peptides circulate within the interstitial fluid, including CSF, and blood vessels through perivascular (e.g. lymphatic) drainage pathways during the crosstalk between the brain and the vascular system [77].”
From Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer’s disease (2020) · cites this paper as [77]
The cited source says what the claim attributes to it.
In the citing paper
“Inflammation does, however, not seem to be a major component in CAA-related microhemorrhage or microinfarction [38], with the exception of a rare clinical subtype: CAA-related inflammation [6].”
From Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer’s disease, but not in cerebral amyloid angiopathy (2021) · cites this paper as [6]
In the citing paper
“AQP4 levels are reduced in CAA; since AQP4 plays a vital role in glymphatic Aβ clearance in AD brain parenchyma, this consequently impairs Aβ clearance [606, 608].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [608]
In the citing paper
“AQP4 levels are reduced in CAA; since AQP4 plays a vital role in glymphatic Aβ clearance in AD brain parenchyma, this consequently impairs Aβ clearance [606, 608].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [608]
In the citing paper
“Chronic inflammation‐induced disruption of the BBB is an early biomarker of human cognitive dysfunction and often leads to dementia, 113 and both Aβ deposits and tau pathology aggravate vascular damage. 114 , 115”
From Senescence, brain inflammation, and oligomeric tau drive cognitive decline in Alzheimer's disease: Evidence from clinical and preclinical studies (2024) · cites this paper as [115]
In the citing paper
“There is overwhelming evidence for cerebrovascular alterations in AD pathology and amyloid-β deposition around leptomeningeal vessels is a hall mark of cerebral amyloid angiopathy, occurring in almost all AD patients”
From Living on the Edge of the CNS: Meninges Cell Diversity in Health and Disease (2021) · cites this paper as Greenberg et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–231 of 231
Hemorrhagic stroke associated with the Iowa amyloid precursor protein mutation
Greenberg, S. M., Shin, Y., Grabowski, T. J., Cooper, G. E., Rebeck, G. W., Iglesias, S., Chapon, F., Tournier‐Lasserve, E., & Baron, J. (2003) · Neurology · doi:10.1212/01.wnl.0000050140.10044.a8 · Cited by 60
Self-citationClusterin contributes to early stage of Alzheimer's disease pathogenesis
Oh, S., Kim, M. S., Park, S., Son, H., Kim, S., Kim, M., Jo, D., Tak, E., & Lee, J. (2018) · Brain Pathology · doi:10.1111/bpa.12660 · Cited by 59
Histopathology of diffusion imaging abnormalities in cerebral amyloid angiopathy
van Veluw, S. J., Reijmer, Y. D., van der Kouwe, A. J. W., Charidimou, A., Riley, G. A., Leemans, A., Bacskai, B. J., Frosch, M. P., Viswanathan, A., & Greenberg, S. M. (2019) · Neurology · doi:10.1212/wnl.0000000000007005 · Cited by 58
Self-citationCerebrovascular contributions to aging and Alzheimer's disease in Down syndrome
Wilcock, D. M., Schmitt, F. A., & Head, E. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.11.007 · Cited by 56
Han, B. W., Zhou, M., Vellimana, A. K., Milner, E., Kim, D. H., Greenberg, J. K., Chu, W., Mach, R. H., & Zipfel, G. J. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-86 · Cited by 55
Matrix metalloproteinase 9–mediated intracerebral hemorrhage induced by cerebral amyloid angiopathy
Zhao, L., Arbel‐Ornath, M., Wang, X., Betensky, R. A., Greenberg, S. M., Frosch, M. P., & Bacskai, B. J. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.07.016 · Cited by 52
Self-citationBrain ApoA-I, ApoJ and ApoE Immunodetection in Cerebral Amyloid Angiopathy
Camacho, J., Moliné, T., Bonaterra‐Pastra, A., y Cajal, S. R., Martínez-Sáez, E. A., & Hernández‐Guillamón, M. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00187 · Cited by 52
Frackowiak, J., Miller, D. L., Potempska, A., Sukontasup, T., & Mazur‐Kolecka, B. (2003) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/62.6.685 · Cited by 49
Zabel, M., Schrag, M., Crofton, A., Tung, S., Beaufond, P., Van Ornam, J., DiNinni, A., Vinters, H. V., Coppola, G., & Kirsch, W. M. (2013) · Brain Pathology · doi:10.1111/bpa.12005 · Cited by 46
Hemorrhage is uncommon in new Alzheimer family with Flemish amyloid precursor protein mutation
Brooks, W. S., Kwok, J. B., Halliday, G. M., Godbolt, A. K., Rossor, M. N., Creasey, H. M., Jones, A. O., & Schofield, P. R. (2004) · Neurology · doi:10.1212/01.wnl.0000142965.10778.c7 · Cited by 43
Cortical thickness mediates the effect of β-amyloid on episodic memory
Villeneuve, S., Reed, B., Wirth, M., Haase, C. M., Madison, C., Ayakta, N., Mack, W., Mungas, D., Chui, H., Decarli, C., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000170 · Cited by 43
Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab
Liu, E., Wang, D., Sperling, R. A., Salloway, S., Fox, N. C., Blennow, K., Scheltens, P., Schmidt, M. E., Streffer, J. R., Novak, G., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005060 · Cited by 42
Self-citationEndo, Y., Hasegawa, K., Nomura, R., Arishima, H., Kikuta, K., Yamashita, T., Inoue, Y., Ueda, M., Ando, Y., Wilson, M. R., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0662-1 · Cited by 42
Clinical Evaluation of Amyloid-Related Imaging Abnormalities in Bapineuzumab Phase III Studies
Brashear, H. R., Ketter, N., Bogert, J., Di, J., Salloway, S., & Sperling, R. A. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180675 · Cited by 39
Self-citationAβ species, including IsoAsp23 Aβ, in Iowa-type familial cerebral amyloid angiopathy
Shin, Y., Cho, H. J., Fukumoto, H., Shimizu, T., Shirasawa, T., Greenberg, S. M., & Rebeck, W. G. (2003) · Acta Neuropathologica · doi:10.1007/s00401-002-0639-0 · Cited by 37
Self-citationCerebral amyloid angiopathy in Down's syndrome.
Belza, M. G., & Urich, H. (1986) · PubMed · Cited by 37
Pathogenic Effects of Cerebral Amyloid Angiopathy Mutations in the Amyloid β‐Protein Precursor
Nostrand, W. E. V., Melchor, J. P., Romanov, G. A., Zeigler, K., & Davis, J. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04824.x · Cited by 36
Inoue, Y., Ueda, M., Tasaki, M., Takeshima, A., Nagatoshi, A., Masuda, T., Misumi, Y., Kosaka, T., Nomura, T., Mizukami, M., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1720-z · Cited by 35
Effects of apoE isoforms on beta-amyloid-induced matrix metalloproteinase-9 in rat astrocytes
Guo, S., Wang, S., Kim, W. J., Lee, S.-R., Frosch, M. P., Bacskai, B. J., Greenberg, S. M., & Lo, E. H. (2006) · Brain Research · doi:10.1016/j.brainres.2006.06.041 · Cited by 34
Self-citationKowa, H., Sakakura, T., Matsuura, Y., Wakabayashi, T., Mann, D. M. A., Duff, K., Tsuji, S., Hashimoto, T., & Iwatsubo, T. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63295-6 · Cited by 34
Ryan, N. S., Lashley, T., Révész, T., Dantu, K., Fox, N. C., & Morris, H. R. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142325 · Cited by 32
Capillary Amyloid-β Protein Deposition in a Population-Based Study (Vantaa 85+)
Mäkelä, M., Paetau, A., Polvikoski, T., Myllykangas, L., & Tanskanen, M. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-150241 · Cited by 31
Bouvy, W. H., van Veluw, S. J., Kuijf, H. J., Zwanenburg, J. J. M., Kappelle, J. L. J., Luijten, P. R., Koek, H. L., Geerlings, M. I., Biessels, G. J., & On behalf of the Utrecht Vascular Cognitive Impairment (VCI) Study Group (2019) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x19838087 · Cited by 30
Sánchez‐Valle, R., Lladó, A., Ezquerra, M., Rey, M. J., Rami, L., & Molinuevo, J. L. (2007) · European Journal of Neurology · doi:10.1111/j.1468-1331.2007.01988.x · Cited by 29
APOE gene polymorphism as a risk factor for cerebral amyloid angiopathy-related hemorrhage.
Nicoll, J. A. R., & McCarron, M. O. (2001) · PubMed · Cited by 27
Blockx, I., Einstein, S., Guns, P., Audekerke, J. V., Guglielmetti, C., Zago, W. M., Roose, D., Verhoye, M., der Linden, A. V., & Bard, F. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160023 · Cited by 23
Alzheimer risk loci and associated neuropathology in a population-based study (Vantaa 85+)
Mäkelä, M., Kaivola, K., Valori, M., Paetau, A. E., Polvikoski, T. M., Singleton, A., Traynor, B. J., Stone, D. J., Peuralinna, T., Tienari, P. J., et al. (2018) · Neurology Genetics · doi:10.1212/nxg.0000000000000211 · Cited by 22
Spontaneous amyloid-related imaging abnormalities in a cognitively normal adult
Raman, M. R., Wiste, H. J., Senjem, M. L., Ward, C. P., Jack, C. R., & Kantarci, K. (2014) · Neurology · doi:10.1212/wnl.0000000000000957 · Cited by 11
Haeberlein, S. B., Castrillo‐Viguera, C., Gheuens, S., Chen, T., O'Gorman, J. T., Chiao, P., Wang, G., von Hehn, C., Skordos, L., Höck, C., et al. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.06.2383 · Cited by 6
Andjelković, M., Abi‐Saab, D., Delmar, P., Pross, N., Voyle, N., Klein, G., Mertes, M., Ristic, S., Martényi, F., da Fontoura, P. P., et al. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.06.2382 · Cited by 6
Insights into the pathogenesis of normal-pressure hydrocephalus
Spina, S. E., & Laws, S. M. (2019) · Neurology · doi:10.1212/wnl.0000000000007495 · Cited by 5
Flagged first, then by citations
1 of the 232 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
Jack, C. R., Andrews, J. S., Beach, T. G., Buracchio, T., Dunn, B., Graf, A., Hansson, O., Ho, C., Jagust, W., McDade, E., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13859 · Cited by 2,803
Self-citationKnopman, D. S., Amieva, H., Petersen, R. C., Chételat, G., Holtzman, D. M., Hyman, B. T., Nixon, R. A., & Jones, D. T. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00269-y · Cited by 2,606
Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease
Guo, T., Zhang, D., Zeng, Y., Huang, T. Y., Xu, H., & Zhao, Y. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00391-7 · Cited by 994
Charidimou, A., Boulouis, G., Frosch, M. P., Baron, J.-C., Pasi, M., Albucher, J. F., Banerjee, G., Barbato, C., Bonneville, F., Brandner, S., et al. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00208-3 · Cited by 723
Self-citationSalloway, S., Chalkias, S., Barkhof, F., Burkett, P., Barakos, J., Purcell, D., Suhy, J., Forrestal, F., Tian, Y., Umans, K., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2021.4161 · Cited by 619
Metadata
- Authors
- Greenberg, S. M., Bacskai, B. J., Hernandez-Guillamon, M., Pruzin, J., Sperling, R., & van Veluw, S. J.
- Affiliations
- Harvard University (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Greenberg, Steven M.
- Venue
- Nature Reviews Neurology
- Published
- 2019-12-11
- Volume
- 16
- Issue
- 1
- Pages
- 30-42
- ISSN
- 1759-4758 (ISSN-L)
- 1759-4766
- PMC
- PMC7268202
- OpenAlex
- W2995183059
- Cited by
- 947
- References
- 232
- Citations by year
- 2026: 146 · 2025: 198 · 2024: 179 · 2023: 154 · 2022: 113 · 2021: 104 · 2020: 52
- FWCI
- 7.92
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature Reviews Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Aging (R01AG026484)
- National Institute of Neurological Disorders and Stroke (RF1NS110054, R01NS096730, U24NS100591)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Intracerebral and Subarachnoid Hemorrhage Research
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- cerebral amyloid angiopathy, Alzheimer's disease, amyloid-beta, amyloid-beta clearance, amyloid-related imaging abnormalities, anti-amyloid immunotherapy, vascular function
- MeSH terms
- Alzheimer Disease, Brain, Humans, Signal Transduction, Amyloid beta-Peptides, Cerebral Amyloid Angiopathy, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
